This editorially independent content is sponsored by Astellas.

Carolyn Majcher, OD, FAAO, FORS, Director, Residency Programs and a professor at Oklahoma College of Optometry, notes how the conversation about geographic atrophy has changed with the introduction of complement inhibitor therapies. As most primary care optometrists have access to OCT technology, the opportunity to detect and potentially start treatments creates the opportunity to preserve vision for more patients.